Romidepsin (Istodax) for Cutaneous T-Cell Lymphoma

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2010年 / 52卷 / 1339期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：42 / 43
页数：2
相关论文
共 50 条
  • [21] Combination treatment with romidepsin and nitrogen mustard demonstrates synergy in cutaneous T-cell lymphoma
    Dulmage, B. O.
    Story, S.
    Geskin, L. J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 : S98 - S98
  • [22] Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin
    Kim, Youn H.
    Demierre, Marie-France
    Kim, Ellen J.
    Lerner, Adam
    Rook, Alain H.
    Duvic, Madeleine
    Robak, Tadeusz
    Samtsov, Alexey
    McCulloch, William
    Chen, Suephy C.
    Waksman, Joel
    Nichols, Jean
    Whittaker, Sean
    LEUKEMIA & LYMPHOMA, 2013, 54 (02) : 284 - 289
  • [23] Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
    Bates, Susan E.
    Zhan, Zhirong
    Steadman, Kenneth
    Obrzut, Tomasz
    Luchenko, Victoria
    Frye, Robin
    Robey, Robert W.
    Turner, Maria
    Gardner, Erin R.
    Figg, William D.
    Steinberg, Seth M.
    Ling, Alex
    Fojo, Tito
    To, Kin Wah
    Piekarz, Richard L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (02) : 256 - 267
  • [24] romidepsin(Istodax)
    隋娜
    郭长彬
    中国药物化学杂志, 2010, 20 (03) : 239 - 239
  • [25] The discovery and development of romidepsin for the treatment of T-cell lymphoma
    Smolewski, Piotr
    Robak, Tadeusz
    EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (08) : 859 - 873
  • [26] Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma
    Cortes, Jose R.
    Patrone, Christina C.
    Quinn, Stuart Aidan
    Gu, Yuhan
    Sanchez-Martin, Marta
    Mackey, Adam
    Cooke, Anisha J.
    Shih, Bobby B.
    Laurent, Anouchka P.
    Trager, Megan H.
    Ferrando, Adolfo A.
    Geskin, Larisa J.
    Palomero, Teresa
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (12) : 2908 - +
  • [27] Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) with tumors and/or folliculotropic involvement.
    Foss, Francine M.
    Duvic, Madeleine
    Lerner, Adam
    Rook, Alain
    Whittaker, Sean
    Kim, Ellen J.
    Kim, Youn H.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases
    Poligone, Brian
    Rubio-Gonzalez, Belen
    Querfeld, Christiane
    DERMATOLOGIC THERAPY, 2019, 32 (02)
  • [29] Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data
    Bates, Susan E.
    Eisch, Robin
    Ling, Alexander
    Rosing, Douglas
    Turner, Maria
    Pittaluga, Stefania
    Prince, H. Miles
    Kirschbaum, Mark H.
    Allen, Steven L.
    Zain, Jasmine
    Geskin, Larisa J.
    Joske, David
    Popplewell, Leslie
    Cowen, Edward W.
    Jaffe, Elaine S.
    Nichols, Jean
    Kennedy, Sally
    Steinberg, Seth M.
    Liewehr, David J.
    Showe, Louise C.
    Steakley, Caryn
    Wright, John
    Fojo, Tito
    Litman, Thomas
    Piekarz, Richard L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (01) : 96 - 109
  • [30] Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma
    Martinez-Escala, M. Estela
    Kuzel, TimothyM.
    Kaplan, Jason B.
    Petrich, Adam
    Nardone, Beatrice
    Rosen, Steven T.
    Guitart, Joan
    JAMA ONCOLOGY, 2016, 2 (06) : 790 - 793
12345